Cerebral Palsy Market Share, Size, Definition, Treatment, Symptoms, Causes, Pipeline Review, H2 2016
Global Markets Direct's, 'Cerebral Palsy - Pipeline Review, H2 2016', provides an overview of the Cerebral Palsy pipeline landscape. Read More @ http://www.radiantinsights.com/research/cerebral-palsy-pipeline-review-h2-2016
Global Markets Direct's, 'Cerebral Palsy - Pipeline Review, H2 2016', provides an overview of the Cerebral Palsy pipeline landscape.
Read More @ http://www.radiantinsights.com/research/cerebral-palsy-pipeline-review-h2-2016
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
- The report assesses <strong>Cerebral</strong> <strong>Palsy</strong> therapeutics based on drug target, mechanism of action (MoA), route of<br />
administration (RoA) and molecule type<br />
- The report summarizes all the dormant and discontinued pipeline projects<br />
- The report reviews latest news related to pipeline therapeutics for <strong>Cerebral</strong> <strong>Palsy</strong><br />
Reasons To Buy<br />
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies<br />
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain<br />
competitive advantage<br />
- Identify and understand important and diverse types of therapeutics under development for <strong>Cerebral</strong> <strong>Palsy</strong><br />
- Identify potential new clients or partners in the target demographic<br />
- Develop strategic initiatives by understanding the focus areas of leading companies<br />
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics<br />
- Devise corrective measures for pipeline projects by understanding <strong>Cerebral</strong> <strong>Palsy</strong> pipeline depth and focus of<br />
Indication therapeutics<br />
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most<br />
attractive projects to enhance and expand business potential and scope<br />
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove<br />
them from pipeline<br />
Buy a Sample Copy of This Report @ http://www.radiantinsights.com/research/cerebral-palsy-pipeline-reviewh2-<strong>2016</strong>/request-sample<br />
Table of Contents<br />
Table of Contents 2<br />
List of Tables 4<br />
List of Figures 4<br />
Introduction 5<br />
Global <strong>Market</strong>s Direct Report Coverage 5<br />
<strong>Cerebral</strong> <strong>Palsy</strong> Overview 6<br />
Therapeutics Development 7<br />
<strong>Pipeline</strong> Products for <strong>Cerebral</strong> <strong>Palsy</strong> - Overview 7<br />
<strong>Cerebral</strong> <strong>Palsy</strong> - Therapeutics under Development by Companies 8<br />
<strong>Cerebral</strong> <strong>Palsy</strong> - <strong>Pipeline</strong> Products Glance 9<br />
Late Stage Products 9<br />
Early Stage Products 10<br />
<strong>Cerebral</strong> <strong>Palsy</strong> - Products under Development by Companies 11<br />
<strong>Cerebral</strong> <strong>Palsy</strong> - Companies Involved in Therapeutics Development 12<br />
Allergan Plc 12<br />
Cell Cure Neurosciences, Ltd. 13<br />
Cellular Biomedicine Group, Inc. 14<br />
CHA Bio & Diostech Co., Ltd. 15<br />
CytoDel, LLC 16<br />
Neuralstem, Inc. 17<br />
<strong>Cerebral</strong> <strong>Palsy</strong> - Therapeutics Assessment 18<br />
Assessment by Monotherapy Products 18<br />
Assessment by Target 19<br />
Assessment by Mechanism of Action 21<br />
Assessment by Route of Administration 22<br />
Assessment by Molecule Type 24<br />
Drug Profiles 26<br />
Cyto-012 - Drug Profile 26<br />
Product Description 26
Change language